Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders

详细信息    查看全文

• 作者：Katelyn N. Nelson¹ ; Malalage N. Peiris¹ ; April N. Meyer¹ ; Asma Siari² ; Daniel J. Donoghue¹ ; ³ ; ^{ddonoghue@ucsd.edu}
• 关键词：leukemia ; lymphoma ; oncogenic fusion ; ALK ; FGFR ; PDGFR.
• 刊名：Trends in Molecular Medicine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：23
• 期：1
• 页码：59-79
• 全文大小：2973 K
• 卷排序：23

文摘

Receptor tyrosine kinases (RTKs) activate various signaling pathways and regulate cellular proliferation, survival, migration, and angiogenesis. Malignant neoplasms often circumvent or subjugate these pathways by promoting RTK overactivation through mutation or chromosomal translocation. RTK translocations create a fusion protein containing a dimerizing partner fused to an RTK kinase domain, resulting in constitutive kinase domain activation, altered RTK cellular localization, upregulation of downstream signaling, and novel pathway activation. While RTK translocations in hematological malignancies are relatively rare, clinical evidence suggests that patients with these genetic abnormalities benefit from RTK-targeted inhibitors. Here, we present a timely review of an exciting field by examining RTK chromosomal translocations in hematological cancers, such as Anaplastic Lymphoma Kinase (ALK), Fibroblast Growth Factor Receptor (FGFR), Platelet-Derived Growth Factor Receptor (PDGFR), REarranged during Transfection (RET), Colony Stimulating Factor 1 Receptor (CSF1R), and Neurotrophic Tyrosine Kinase Receptor Type 3 (NTRK3) fusions, and discuss current therapeutic options.